Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 159 entries
Sorted by: Best Match Show Resources per page
Genomic Rearrangements and Functional Diversification of lecA and lecB Lectin-Coding Regions Impacting the Efficacy of Glycomimetics Directed against Pseudomonas aeruginosa.

Frontiers in microbiology

Boukerb AM, Decor A, Ribun S, Tabaroni R, Rousset A, Commin L, Buff S, Doléans-Jordheim A, Vidal S, Varrot A, Imberty A, Cournoyer B.
PMID: 27303392
Front Microbiol. 2016 May 31;7:811. doi: 10.3389/fmicb.2016.00811. eCollection 2016.

LecA and LecB tetrameric lectins take part in oligosaccharide-mediated adhesion-processes of Pseudomonas aeruginosa. Glycomimetics have been designed to block these interactions. The great versatility of P. aeruginosa suggests that the range of application of these glycomimetics could be restricted...

Cite
Boukerb AM, Decor A, Ribun S, et al. Genomic Rearrangements and Functional Diversification of lecA and lecB Lectin-Coding Regions Impacting the Efficacy of Glycomimetics Directed against Pseudomonas aeruginosa. Front Microbiol. 2016;7:811doi: 10.3389/fmicb.2016.00811.
Boukerb, A. M., Decor, A., Ribun, S., Tabaroni, R., Rousset, A., Commin, L., Buff, S., Doléans-Jordheim, A., Vidal, S., Varrot, A., Imberty, A., & Cournoyer, B. (2016). Genomic Rearrangements and Functional Diversification of lecA and lecB Lectin-Coding Regions Impacting the Efficacy of Glycomimetics Directed against Pseudomonas aeruginosa. Frontiers in microbiology, 7811. https://doi.org/10.3389/fmicb.2016.00811
Boukerb, Amine M, et al. "Genomic Rearrangements and Functional Diversification of lecA and lecB Lectin-Coding Regions Impacting the Efficacy of Glycomimetics Directed against Pseudomonas aeruginosa." Frontiers in microbiology vol. 7 (2016): 811. doi: https://doi.org/10.3389/fmicb.2016.00811
Boukerb AM, Decor A, Ribun S, Tabaroni R, Rousset A, Commin L, Buff S, Doléans-Jordheim A, Vidal S, Varrot A, Imberty A, Cournoyer B. Genomic Rearrangements and Functional Diversification of lecA and lecB Lectin-Coding Regions Impacting the Efficacy of Glycomimetics Directed against Pseudomonas aeruginosa. Front Microbiol. 2016 May 31;7:811. doi: 10.3389/fmicb.2016.00811. eCollection 2016. PMID: 27303392; PMCID: PMC4885879.
Copy Download .nbib Format: NLM
Short-term effectiveness of a culturally tailored educational intervention on foot self-care among type 2 diabetes patients in Morocco.

Journal of clinical & translational endocrinology

Adarmouch L, Elyacoubi A, Dahmash L, El Ansari N, Sebbani M, Amine M.
PMID: 29067251
J Clin Transl Endocrinol. 2017 Feb 09;7:54-59. doi: 10.1016/j.jcte.2017.01.002. eCollection 2017 Mar.

BACKGROUND: Self-management education (SME) is an important yet unacknowledged aspect of diabetes care. Despite the raise of diabetes and its complications with significant burden in developing countries, research on SME interventions in Morocco is lacking.AIMS: To assess the effectiveness...

Cite
Adarmouch L, Elyacoubi A, Dahmash L, et al. Short-term effectiveness of a culturally tailored educational intervention on foot self-care among type 2 diabetes patients in Morocco. J Clin Transl Endocrinol. 2017;7:54-59doi: 10.1016/j.jcte.2017.01.002.
Adarmouch, L., Elyacoubi, A., Dahmash, L., El Ansari, N., Sebbani, M., & Amine, M. (2017). Short-term effectiveness of a culturally tailored educational intervention on foot self-care among type 2 diabetes patients in Morocco. Journal of clinical & translational endocrinology, 754-59. https://doi.org/10.1016/j.jcte.2017.01.002
Adarmouch, Latifa, et al. "Short-term effectiveness of a culturally tailored educational intervention on foot self-care among type 2 diabetes patients in Morocco." Journal of clinical & translational endocrinology vol. 7 (2017): 54-59. doi: https://doi.org/10.1016/j.jcte.2017.01.002
Adarmouch L, Elyacoubi A, Dahmash L, El Ansari N, Sebbani M, Amine M. Short-term effectiveness of a culturally tailored educational intervention on foot self-care among type 2 diabetes patients in Morocco. J Clin Transl Endocrinol. 2017 Feb 09;7:54-59. doi: 10.1016/j.jcte.2017.01.002. eCollection 2017 Mar. PMID: 29067251; PMCID: PMC5651287.
Copy Download .nbib Format: NLM
Utilization of a ts-sacB selection system for the generation of a Mycobacterium avium serovar-8 specific glycopeptidolipid allelic exchange mutant.

Annals of clinical microbiology and antimicrobials

Irani VR, Lee SH, Eckstein TM, Inamine JM, Belisle JT, Maslow JN.
PMID: 15458565
Ann Clin Microbiol Antimicrob. 2004 Sep 30;3:18. doi: 10.1186/1476-0711-3-18.

BACKGROUND: Mycobacterium avium are ubiquitous environmental organisms and a cause of disseminated infection in patients with end-stage AIDS. The glycopeptidolipids (GPL) of M. avium are proposed to participate in the pathogenesis of this organism, however, establishment of a clear...

Cite
Irani VR, Lee SH, Eckstein TM, et al. Utilization of a ts-sacB selection system for the generation of a Mycobacterium avium serovar-8 specific glycopeptidolipid allelic exchange mutant. Ann Clin Microbiol Antimicrob. 2004;3:18doi: 10.1186/1476-0711-3-18.
Irani, V. R., Lee, S. H., Eckstein, T. M., Inamine, J. M., Belisle, J. T., & Maslow, J. N. (2004). Utilization of a ts-sacB selection system for the generation of a Mycobacterium avium serovar-8 specific glycopeptidolipid allelic exchange mutant. Annals of clinical microbiology and antimicrobials, 318. https://doi.org/10.1186/1476-0711-3-18
Irani, Vida R, et al. "Utilization of a ts-sacB selection system for the generation of a Mycobacterium avium serovar-8 specific glycopeptidolipid allelic exchange mutant." Annals of clinical microbiology and antimicrobials vol. 3 (2004): 18. doi: https://doi.org/10.1186/1476-0711-3-18
Irani VR, Lee SH, Eckstein TM, Inamine JM, Belisle JT, Maslow JN. Utilization of a ts-sacB selection system for the generation of a Mycobacterium avium serovar-8 specific glycopeptidolipid allelic exchange mutant. Ann Clin Microbiol Antimicrob. 2004 Sep 30;3:18. doi: 10.1186/1476-0711-3-18. PMID: 15458565; PMCID: PMC524182.
Copy Download .nbib Format: NLM
Contemporary multidisciplinary treatment of pregnancy-associated breast cancer.

SpringerPlus

Meisel JL, Economy KE, Calvillo KZ, Schapira L, Tung NM, Gelber S, Kereakoglow S, Partridge AH, Mayer EL.
PMID: 23888269
Springerplus. 2013 Jul 03;2(1):297. doi: 10.1186/2193-1801-2-297. Print 2013 Dec.

Breast cancer diagnosed during pregnancy poses unique challenges. Application of standard treatment algorithms is limited by lack of level I evidence from randomized trials. This study describes contemporary multidisciplinary treatment of pregnancy-associated breast cancer (PABC) in an academic setting...

Cite
Meisel JL, Economy KE, Calvillo KZ, et al. Contemporary multidisciplinary treatment of pregnancy-associated breast cancer. Springerplus. 2013;2(1):297doi: 10.1186/2193-1801-2-297.
Meisel, J. L., Economy, K. E., Calvillo, K. Z., Schapira, L., Tung, N. M., Gelber, S., Kereakoglow, S., Partridge, A. H., & Mayer, E. L. (2013). Contemporary multidisciplinary treatment of pregnancy-associated breast cancer. SpringerPlus, 2(1), 297. https://doi.org/10.1186/2193-1801-2-297
Meisel, Jane L, et al. "Contemporary multidisciplinary treatment of pregnancy-associated breast cancer." SpringerPlus vol. 2,1 (2013): 297. doi: https://doi.org/10.1186/2193-1801-2-297
Meisel JL, Economy KE, Calvillo KZ, Schapira L, Tung NM, Gelber S, Kereakoglow S, Partridge AH, Mayer EL. Contemporary multidisciplinary treatment of pregnancy-associated breast cancer. Springerplus. 2013 Jul 03;2(1):297. doi: 10.1186/2193-1801-2-297. Print 2013 Dec. PMID: 23888269; PMCID: PMC3710403.
Copy Download .nbib Format: NLM
Large impacted upper ureteral calculi: A comparative study between retrograde ureterolithotripsy and percutaneous antegrade ureterolithotripsy in the modified lateral position.

Urology annals

Moufid K, Abbaka N, Touiti D, Adermouch L, Amine M, Lezrek M.
PMID: 24049373
Urol Ann. 2013 Jul;5(3):140-6. doi: 10.4103/0974-7796.115729.

CONTEXT: The treatment for patients with large impacted proximal ureteral stone remains controversial, especially at institutions with limited resources.AIM: The aim of this study is to compare and to evaluate the outcome and complications of two main treatment procedures...

Cite
Moufid K, Abbaka N, Touiti D, et al. Large impacted upper ureteral calculi: A comparative study between retrograde ureterolithotripsy and percutaneous antegrade ureterolithotripsy in the modified lateral position. Urol Ann. 2013;5(3):140-6doi: 10.4103/0974-7796.115729.
Moufid, K., Abbaka, N., Touiti, D., Adermouch, L., Amine, M., & Lezrek, M. (2013). Large impacted upper ureteral calculi: A comparative study between retrograde ureterolithotripsy and percutaneous antegrade ureterolithotripsy in the modified lateral position. Urology annals, 5(3), 140-6. https://doi.org/10.4103/0974-7796.115729
Moufid, Kamal, et al. "Large impacted upper ureteral calculi: A comparative study between retrograde ureterolithotripsy and percutaneous antegrade ureterolithotripsy in the modified lateral position." Urology annals vol. 5,3 (2013): 140-6. doi: https://doi.org/10.4103/0974-7796.115729
Moufid K, Abbaka N, Touiti D, Adermouch L, Amine M, Lezrek M. Large impacted upper ureteral calculi: A comparative study between retrograde ureterolithotripsy and percutaneous antegrade ureterolithotripsy in the modified lateral position. Urol Ann. 2013 Jul;5(3):140-6. doi: 10.4103/0974-7796.115729. PMID: 24049373; PMCID: PMC3764891.
Copy Download .nbib Format: NLM
Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors.

Oncoimmunology

Lerret NM, Marzo AL.
PMID: 23525138
Oncoimmunology. 2013 Feb 01;2(2):e22731. doi: 10.4161/onci.22731.

The major objectives of tumor vaccination are to induce the regression of established tumors and to favor the establishment of long-lasting tumor-specific immunity, capable of protecting the host from relapse. Immunotherapeutic strategies such as the administration of tumor-associated antigenic...

Cite
Lerret NM, Marzo AL. Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors. Oncoimmunology. 2013;2(2):e22731doi: 10.4161/onci.22731.
Lerret, N. M., & Marzo, A. L. (2013). Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors. Oncoimmunology, 2(2), e22731. https://doi.org/10.4161/onci.22731
Lerret, Nadine M, and Marzo, Amanda L. "Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors." Oncoimmunology vol. 2,2 (2013): e22731. doi: https://doi.org/10.4161/onci.22731
Lerret NM, Marzo AL. Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors. Oncoimmunology. 2013 Feb 01;2(2):e22731. doi: 10.4161/onci.22731. PMID: 23525138; PMCID: PMC3601156.
Copy Download .nbib Format: NLM
A comparative, population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses.

Endocrine connections

Vaninetti NM, Clarke DB, Zwicker DA, Yip CE, Tugwell B, Doucette S, Theriault C, Aldahmani K, Imran SA.
PMID: 29712721
Endocr Connect. 2018 May;7(5):768-776. doi: 10.1530/EC-18-0065. Epub 2018 Apr 30.

PURPOSE: Sellar masses may present either with clinical manifestations of mass effect/hormonal dysfunction (CMSM) or incidentally on imaging (pituitary incidentaloma (PI)). This novel population-based study compares these two entities.METHODS: Retrospective analysis of all patients within a provincial pituitary registry...

Cite
Vaninetti NM, Clarke DB, Zwicker DA, et al. A comparative, population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses. Endocr Connect. 2018;7(5):768-776doi: 10.1530/EC-18-0065.
Vaninetti, N. M., Clarke, D. B., Zwicker, D. A., Yip, C. E., Tugwell, B., Doucette, S., Theriault, C., Aldahmani, K., & Imran, S. A. (2018). A comparative, population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses. Endocrine connections, 7(5), 768-776. https://doi.org/10.1530/EC-18-0065
Vaninetti, Nadine M, et al. "A comparative, population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses." Endocrine connections vol. 7,5 (2018): 768-776. doi: https://doi.org/10.1530/EC-18-0065
Vaninetti NM, Clarke DB, Zwicker DA, Yip CE, Tugwell B, Doucette S, Theriault C, Aldahmani K, Imran SA. A comparative, population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses. Endocr Connect. 2018 May;7(5):768-776. doi: 10.1530/EC-18-0065. Epub 2018 Apr 30. PMID: 29712721; PMCID: PMC5970276.
Copy Download .nbib Format: NLM
Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish.

Frontiers in behavioral neuroscience

Savoldi R, Polari D, Pinheiro-da-Silva J, Silva PF, Lobao-Soares B, Yonamine M, Freire FAM, Luchiari AC.
PMID: 28804451
Front Behav Neurosci. 2017 Jul 28;11:139. doi: 10.3389/fnbeh.2017.00139. eCollection 2017.

The combined infusion of

Cite
Savoldi R, Polari D, Pinheiro-da-Silva J, et al. Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish. Front Behav Neurosci. 2017;11:139doi: 10.3389/fnbeh.2017.00139.
Savoldi, R., Polari, D., Pinheiro-da-Silva, J., Silva, P. F., Lobao-Soares, B., Yonamine, M., Freire, F. A. M., & Luchiari, A. C. (2017). Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish. Frontiers in behavioral neuroscience, 11139. https://doi.org/10.3389/fnbeh.2017.00139
Savoldi, Robson, et al. "Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish." Frontiers in behavioral neuroscience vol. 11 (2017): 139. doi: https://doi.org/10.3389/fnbeh.2017.00139
Savoldi R, Polari D, Pinheiro-da-Silva J, Silva PF, Lobao-Soares B, Yonamine M, Freire FAM, Luchiari AC. Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish. Front Behav Neurosci. 2017 Jul 28;11:139. doi: 10.3389/fnbeh.2017.00139. eCollection 2017. PMID: 28804451; PMCID: PMC5532431.
Copy Download .nbib Format: NLM
Publisher Correction: Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus.

Nature communications

Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B.
PMID: 29233961
Nat Commun. 2017 Dec 12;8(1):2137. doi: 10.1038/s41467-017-01779-8.

In the original PDF version of this Article, which was published on 16 October 2017, the publication date was incorrectly given as 10 October 2017. This has now been corrected in the PDF; the HTML version of the paper...

Cite
Llorente C, Jepsen P, Inamine T, et al. Publisher Correction: Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017;8(1):2137doi: 10.1038/s41467-017-01779-8.
Llorente, C., Jepsen, P., Inamine, T., Wang, L., Bluemel, S., Wang, H. J., Loomba, R., Bajaj, J. S., Schubert, M. L., Sikaroodi, M., Gillevet, P. M., Xu, J., Kisseleva, T., Ho, S. B., DePew, J., Du, X., Sørensen, H. T., Vilstrup, H., Nelson, K. E., Brenner, D. A., Fouts, D. E., & Schnabl, B. (2017). Publisher Correction: Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nature communications, 8(1), 2137. https://doi.org/10.1038/s41467-017-01779-8
Llorente, Cristina, et al. "Publisher Correction: Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus." Nature communications vol. 8,1 (2017): 2137. doi: https://doi.org/10.1038/s41467-017-01779-8
Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B. Publisher Correction: Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017 Dec 12;8(1):2137. doi: 10.1038/s41467-017-01779-8. PMID: 29233961; PMCID: PMC5727102.
Copy Download .nbib Format: NLM
Racial and Ethnic Disparities in the Burden and Cost of Diabetes for US Medicare Beneficiaries.

Health equity

Glantz NM, Duncan I, Ahmed T, Fan L, Reed BL, Kalirai S, Kerr D.
PMID: 31289781
Health Equity. 2019 May 15;3(1):211-218. doi: 10.1089/heq.2019.0004. eCollection 2019.

No abstract available.

Cite
Glantz NM, Duncan I, Ahmed T, et al. Racial and Ethnic Disparities in the Burden and Cost of Diabetes for US Medicare Beneficiaries. Health Equity. 2019;3(1):211-218doi: 10.1089/heq.2019.0004.
Glantz, N. M., Duncan, I., Ahmed, T., Fan, L., Reed, B. L., Kalirai, S., & Kerr, D. (2019). Racial and Ethnic Disparities in the Burden and Cost of Diabetes for US Medicare Beneficiaries. Health equity, 3(1), 211-218. https://doi.org/10.1089/heq.2019.0004
Glantz, Namino M, et al. "Racial and Ethnic Disparities in the Burden and Cost of Diabetes for US Medicare Beneficiaries." Health equity vol. 3,1 (2019): 211-218. doi: https://doi.org/10.1089/heq.2019.0004
Glantz NM, Duncan I, Ahmed T, Fan L, Reed BL, Kalirai S, Kerr D. Racial and Ethnic Disparities in the Burden and Cost of Diabetes for US Medicare Beneficiaries. Health Equity. 2019 May 15;3(1):211-218. doi: 10.1089/heq.2019.0004. eCollection 2019. PMID: 31289781; PMCID: PMC6608694.
Copy Download .nbib Format: NLM
Common genetic variants, acting additively, are a major source of risk for autism.

Molecular autism

Klei L, Sanders SJ, Murtha MT, Hus V, Lowe JK, Willsey AJ, Moreno-De-Luca D, Yu TW, Fombonne E, Geschwind D, Grice DE, Ledbetter DH, Lord C, Mane SM, Martin CL, Martin DM, Morrow EM, Walsh CA, Melhem NM, Chaste P, Sutcliffe JS, State MW, Cook EH, Roeder K, Devlin B.
PMID: 23067556
Mol Autism. 2012 Oct 15;3(1):9. doi: 10.1186/2040-2392-3-9.

BACKGROUND: Autism spectrum disorders (ASD) are early onset neurodevelopmental syndromes typified by impairments in reciprocal social interaction and communication, accompanied by restricted and repetitive behaviors. While rare and especially de novo genetic variation are known to affect liability, whether...

Cite
Klei L, Sanders SJ, Murtha MT, et al. Common genetic variants, acting additively, are a major source of risk for autism. Mol Autism. 2012;3(1):9doi: 10.1186/2040-2392-3-9.
Klei, L., Sanders, S. J., Murtha, M. T., Hus, V., Lowe, J. K., Willsey, A. J., Moreno-De-Luca, D., Yu, T. W., Fombonne, E., Geschwind, D., Grice, D. E., Ledbetter, D. H., Lord, C., Mane, S. M., Martin, C. L., Martin, D. M., Morrow, E. M., Walsh, C. A., Melhem, N. M., Chaste, P., Sutcliffe, J. S., State, M. W., Cook, E. H., Roeder, K., & Devlin, B. (2012). Common genetic variants, acting additively, are a major source of risk for autism. Molecular autism, 3(1), 9. https://doi.org/10.1186/2040-2392-3-9
Klei, Lambertus, et al. "Common genetic variants, acting additively, are a major source of risk for autism." Molecular autism vol. 3,1 (2012): 9. doi: https://doi.org/10.1186/2040-2392-3-9
Klei L, Sanders SJ, Murtha MT, Hus V, Lowe JK, Willsey AJ, Moreno-De-Luca D, Yu TW, Fombonne E, Geschwind D, Grice DE, Ledbetter DH, Lord C, Mane SM, Martin CL, Martin DM, Morrow EM, Walsh CA, Melhem NM, Chaste P, Sutcliffe JS, State MW, Cook EH, Roeder K, Devlin B. Common genetic variants, acting additively, are a major source of risk for autism. Mol Autism. 2012 Oct 15;3(1):9. doi: 10.1186/2040-2392-3-9. PMID: 23067556; PMCID: PMC3579743.
Copy Download .nbib Format: NLM
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

Future oncology (London, England)

O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH.
PMID: 34636255
Future Oncol. 2021 Dec;17(34):4665-4676. doi: 10.2217/fon-2021-0753. Epub 2021 Oct 12.

This report describes the rationale, purpose and design of A011801 (CompassHER2 RD), an ongoing prospective, multicenter, Phase III randomized trial. Eligible patients in the United States (US) and Canada with high-risk (defined as ER-negative and/or node-positive) HER2-positive (HER2+) residual...

Cite
O'Sullivan CC, Ballman KV, McCall L, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021;17(34):4665-4676doi: 10.2217/fon-2021-0753.
O'Sullivan, C. C., Ballman, K. V., McCall, L., Kommalapati, A., Zemla, T., Weiss, A., Mitchell, M., Blinder, V., Tung, N. M., Irvin, W. J., Lee, M., Goetz, M. P., Symmans, W. F., Borges, V. F., Krop, I., Carey, L. A., & Partridge, A. H. (2021). Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future oncology (London, England), 17(34), 4665-4676. https://doi.org/10.2217/fon-2021-0753
O'Sullivan, Ciara C, et al. "Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer." Future oncology (London, England) vol. 17,34 (2021): 4665-4676. doi: https://doi.org/10.2217/fon-2021-0753
O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021 Dec;17(34):4665-4676. doi: 10.2217/fon-2021-0753. Epub 2021 Oct 12. PMID: 34636255; PMCID: PMC8600597.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 159 entries